Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial

Lyliana G. Nasib, PhD; Inge Winter-van Rossum, PhD; Nicolaas P. A. Zuithoff, PhD; Zimbo S. R. M. Boudewijns, PhD; Stefan Leucht, MD, PhD; René S. Kahn, MD, PhD

J Clin Psychiatry 2023;84(3):22m14531

ABSTRACT

Objective: In the majority of randomized controlled trials (RCTs) conducted in schizophrenia populations, patients suffering from a substance use disorder (SUD) or suicidality are excluded. Excluding these patients from RCTs might impact the generalizability of results. The aim of this study is to determine whether excluding patients with suicidality and/or SUD impacts RCT results on symptomatic remission, premature study discontinuation, symptom severity, and social functioning.

Methods: Across Europe and Israel, 481 patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder, based on DSM-IV criteria, were recruited between May 26, 2011, and May 15, 2016, for the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) trial. Baseline characteristics and follow-up assessments were compared between patients with versus without baseline SUD and/or suicidality.

Results: A total of 446 patients met eligibility criteria for the OPTiMiSE trial and initiated amisulpride treatment, of whom 404 (91%) had data available on suicidality, SUD, duration of illness, and CDS score. Of the 360 eligible patients with baseline data on suicidality and SUD, 106 patients had comorbid suicidality and/or SUD while 254 patients had neither of these comorbidities. No significant differences in the likelihood to achieve symptomatic remission or to prematurely discontinue the study were found when comparing comorbid versus non-comorbid patients (P = .27). There were no significant differences in symptom severity and social functioning between the groups. Comorbid patients had a higher level of depressive symptoms and more impaired social functioning compared to non-comorbid patients.

Discussion: Excluding first-episode schizophrenia patients with comorbidities from clinical trials unlikely affects key outcome measures. It is recommended to include patients with comorbidities in clinical trials while carefully monitoring suicidality and implementing safety plans to gain insight into efficacy and safety of treatment in this substantial patient population.

Trial Registration: ClinicalTrials.gov identifier: NCT01248195

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (30)

Wong JJ, Jones N, Timko C, et al. Exclusion criteria and generalizability in bipolar disorder treatment trials. Contemp Clin Trials Commun. 2018;9:130–134. PubMed CrossRef
Humphreys K. A review of the impact of exclusion criteria on the generalizability of schizophrenia treatment research. Clin Schizophr Relat Psychoses. 2017;11(1):49–57. PubMed CrossRef
Hoertel N, Le Strat Y, Lavaud P, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2013;74(3):265–270. PubMed CrossRef
Karcher H, Fu S, Meng J, et al; GetReal Consortium Work Package 2. The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials. BMC Med Res Methodol. 2018;18(1):75. PubMed CrossRef
Taipale H, Schneider-Thoma J, Pinzón-Espinosa J, et al. Representation and outcomes of individuals with schizophrenia seen in everyday practice who are ineligible for randomized clinical trials. JAMA Psychiatry. 2022;79(3):210–218. PubMed CrossRef
Boter H, Derks EM, Fleischhacker WW, et al; EUFEST Study Group. Generalizability of the results of efficacy trials in first-episode schizophrenia: comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2010;71(1):58–65. PubMed CrossRef
Riedel M, Leucht S, Rüther E, et al. Critical trial-related criteria in acute schizophrenia studies. Eur Arch Psychiatry Clin Neurosci. 2012;262(2):151–155. PubMed CrossRef
Sher L, Kahn RS. Suicide in schizophrenia: an educational overview. Medicina (Kaunas). 2019;55(7):361. PubMed CrossRef
Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 2018;191(August):234–258. PubMed CrossRef
Winklbaur B, Ebner N, Sachs G, et al. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37–43. PubMed CrossRef
Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?”. Lancet. 2005;365(9453):82–93. PubMed CrossRef
Nordon C, Bovagnet T, Belger M, et al; IMI GetReal WP2 group. Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: a case study using the SOHO database. Schizophr Res. 2018;193:146–153. PubMed CrossRef
Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol. 2005;40(1):27–35. PubMed CrossRef
Leucht S, Winter-van Rossum I, Heres S, et al. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015;41(3):549–558. PubMed CrossRef
Kahn RS, Winter van Rossum I, Leucht S, et al; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018;5(10):797–807. PubMed CrossRef
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441–449. PubMed CrossRef
Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry suppl. 1993;163(22):39–44. PubMed CrossRef
Guy W. Clinical Global Impression (CGI). ECDEU Assess Man Psychopharmacol. 1976:125–126. https://www.psywellness.com.sg/docs/CGI.pdf.
Nasrallah H, Morosini P, Gagnon DD. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res. 2008;161(2):213–224. PubMed CrossRef
Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer Series in Statistics. Vol. 608. New York: Springer; 2001.
IBM. IBM SPSS Statistics Software for Windows, Version 25. IBM. doi:10.1016/j.jchf.2014.02.009.
SAS Institute Inc. Cary, NC U. Sas 9.4. Cary, NC: SAS Inst Inc; 2017.
Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005;112(2):141–148. PubMed CrossRef
Austad G, Joa I, Johannessen JO, et al. Gender differences in suicidal behaviour in patients with first-episode psychosis. Early Interv Psychiatry. 2015;9(4):300–307. PubMed CrossRef
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–1277. PubMed CrossRef
FDA. Guidance for Industry: Suicidal Ideation and Behavior: Prospective Assessment of Occurrence in Clinical Trials. Center for Drug Evaluation and Research. FDA website. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-suicidal-ideation-and-behavior-prospective-assessment-occurrence-clinical-trials.
Pelizza L, Pellegrini C, Quattrone E, et al. Suicidal thinking and behavior in first episode schizophrenia: findings from the 24-month follow-up of the “Parma Early Psychosis” program. Arch Suicide Res. 2020;26(2):656–676. PubMed CrossRef
Cotton SM, Lambert M, Schimmelmann BG, et al. Differences between first episode schizophrenia and schizoaffective disorder. Schizophr Res. 2013;147(1):169–174. PubMed CrossRef